$ENTB Regen BioPharma Inc. (OTCQB: RGBPP) In a recent study published in the International Journal of Molecular Sciences a team of scientists in Guangzhou, China[1] have demonstrated that expression of NR2F6 in patients with early cervical cancer correlates with poor prognoses. These scientists tested for NR2F6 in patient's cervical cancer tissue as well as in the normal tissue surrounding each of their tumors.
http://www.otcmarkets.com/stock/ENTB/news